Učitavanje...
Use of anti-TNF drug levels to optimise patient management
Anti-tumour necrosis factor (TNF) therapies, such as infliximab, adalimumab, certolizumab pegol and golimumab, have been proven to be effective for the treatment of patients with Crohn's disease and ulcerative colitis. However, 10%–30% of patients with inflammatory bowel disease (IBD) show no i...
Spremljeno u:
| Izdano u: | Frontline Gastroenterol |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMJ Publishing Group
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5369499/ https://ncbi.nlm.nih.gov/pubmed/28839870 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/flgastro-2016-100685 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|